Ingenus Pharmaceuticals Announces FDA Approval and Launch of First and Only Generic Equivalent to Premarin® Tablets (Conjugated Estrogens Tablets, USP) - BioSpace
Ingenus Pharmaceuticals Announces FDA Approval and Launch of First and Only Generic Equivalent to Premarin® Tablets (Conjugated Estrogens Tablets, USP) BioSpace
Unusual histopathologic findings of appendectomy specimens: A retrospective study of cases at Jordan University Hospital over the last decade (2015-2024).
To investigate the incidence and nature of unusual histopathological findings in appendectomy specimens and assess their impact on post-appendectomy management.
Global trends in the uptake of specialist diagnostic ultrasound and MRI scans for endometriosis: An international cross-sectional survey.
Endometriosis affects 1 in 10 women globally. We aimed to determine health provider involvement and preferred methods of obtaining an endometriosis diagnosis across international jurisdictions. A global cross-sectional survey, distributed …
Endometriosis During Peri-Menopause and Post-Menopause: A Review of the Literature.
Endometriosis is traditionally regarded as a condition predominantly affecting women of reproductive age, often associated with infertility and cyclical pelvic pain. As a result, a significant body of research and …
Natural procreative technology (NaProTechnology) for infertility: take-home baby rate and clinical outcomes in a 5-year single-center cohort of 1,310 couples.
Assisted reproductive technologies (ART) are widely used to address infertility; however, they are costly, associated with medical risks, and often yield suboptimal clinical outcomes. Natural Procreative Technology, also known as …
Ingenus Pharmaceuticals Announces FDA Approval and Launch of First and Only Generic Equivalent to Premarin® Tablets (Conjugated Estrogens Tablets, USP) - Morningstar
Ingenus Pharmaceuticals Announces FDA Approval and Launch of First and Only Generic Equivalent to Premarin® Tablets (Conjugated Estrogens Tablets, USP) Morningstar
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어